Due to the sharp decline in sales of COVID-19 products of roughly CHF 5 billion, Roche expects a decrease in Group sales in the low single digit range. Excluding this COVID-19 sales decline, Roche anticipates solid underlying sales growth in both divisions. Core earnings per share are targeted to develop broadly in line with sales decline. Roche expects to further increase its dividend in Swiss francs.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
- [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
- Roche reports EC approves label expansion of Hemlibra
- European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
- Roche price target lowered to CHF 350 from CHF 380 at Berenberg